Collegium Pharmaceutical Inc., of Canton, Mass., said phase III data published in Pain showed that Xtampza (oxycodone extended-release capsules) met its primary endpoint, with a statistically significant difference in average pain intensity from randomization baseline to week 12 between the Xtampza ER and placebo groups (p = 0.0001).